Advertisement
Canada markets close in 5 hours 41 minutes

  • S&P/TSX

    21,601.95
    -138.25 (-0.64%)
     

  • S&P 500

    5,062.23
    +0.41 (+0.01%)
     

  • DOW

    37,884.00
    +148.89 (+0.39%)
     

  • CAD/USD

    0.7231
    -0.0022 (-0.31%)
     

  • CRUDE OIL

    85.10
    -0.31 (-0.36%)
     

  • Bitcoin CAD

    87,191.87
    -3,457.33 (-3.81%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,385.90
    +2.90 (+0.12%)
     

  • RUSSELL 2000

    1,956.08
    -19.63 (-0.99%)
     

  • 10-Yr Bond

    4.6720
    +0.0440 (+0.95%)
     

  • NASDAQ

    15,909.76
    +24.74 (+0.16%)
     

  • VOLATILITY

    19.10
    -0.13 (-0.68%)
     

  • FTSE

    7,804.36
    -161.17 (-2.02%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • CAD/EUR

    0.6791
    -0.0033 (-0.48%)
     
MARKETS LIVE BLOG:

STOCKS TRADE HIGHER AS COMPANY EARNINGS ROLL IN

Bond yields continue to rise after 10-year Treasury yield touched 2024 highs on Monday

Aravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare Conference

Aravive, Inc.
·2 min read

HOUSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021 at 9:20 AM ET. Aravive will also participate in one-on-one meetings at the conference.

This conference is being held virtually, and a live webcast will be accessible on the Events & Presentations page of www.aravive.com. An archived replay of the webcast will be available for 90 days following the webcast.

About Aravive
Aravive, Inc. is a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases. Aravive’s lead therapeutic, AVB-500, is a first-in-class ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment and decreased survival. AVB-500 has the potential to be combined with multiple anticancer therapies across several tumor types, due to its novel mechanism of action and favorable safety profile. AVB-500 has been granted Fast Track Designation by the U.S. Food and Drug Administration in platinum resistant recurrent ovarian cancer. The Company is currently evaluating AVB-500 in a registrational Phase 3 trial in platinum resistant ovarian cancer, a Phase 1b/2 trial in second line plus, clear cell renal cell carcinoma, and a Phase 1b/2 trial in first-line treatment of pancreatic adenocarcinoma. The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. For more information, please visit www.aravive.com.

Contact:
Joseph T. Schepers
VP, Investor Relations, Aravive, Inc.
jschepers@aravive.com
(770) 558-5517